Published Date : Sep 12, 2016
Albany, NY, Sep 12, 2016: MarketResearchReports.biz has announced the addition of a new research report to its vast repository. The research report, titled “Global Diabetes And Obesity Drugs Market To 2022 - Insulins And GPCRs Retain Commercial Prominence, While High Unmet Need Remains In Weight Loss Treatment,” offers a comprehensive overview of the global diabetes and obesity drugs market. Diabetes, categorized as type 1, type 2, and juvenile diabetes, is a result of dysfunctional insulin secretion or absorption. In the long term, this non-communicable condition can result in a multiple organ failure which could include nerves, kidneys, heart, and blood vessels amongst others.
The biggest problem worsening diabetes for existing patients and putting several at risk is the issue of obesity. Bigger the waistline, higher is the risk of diabetes and other diabetic complications. Thus, several obese people with diabetes are advised to reduce weight and shed off the excessive fat in order to contain their condition. Prescriptions of drugs that aid weight loss are thus propelling the growth of the global diabetes and obesity drugs market. The demand for obesity-fighting drugs is also gaining traction as rising number of drug manufacturing companies are making affordable drugs that deliver the required results. Analysts project that high prevalence of diabetes is likely to augment the growth of the global market in the coming years.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/799451
The steady market drivers are being shadowed by the restraints such as the risk of cancer and other cardiovascular complications that are associated with long-term intake of obesity drugs for diabetes. However, the ongoing efforts by manufacturers to make these drugs safer and reliable is expected to create a sizeable demand for the obesity drugs market. Furthermore, the growing number of diabetics and the huge population base in developing countries of India, Japan, and China are anticipated to open up new opportunities for the global diabetes and obesity drugs market. The increasing popularity of type 2 diabetes mellitus (T2DM) drugs in the pipeline is poised to provide an incredible impetus to the overall market in the coming years.
Some of the key players operating in the global diabetes and obesity drugs market are Sanofi, Novo Nordisk, Eli Lilly, and Merck & Co. Some of the popularly sold drugs by these companies are Lantus, Novolog, Januvia, Levemir, Victoza, Humalog, and Janumet. Some of the new entrants identified by the research analysts are Saxenda, Xenical, Belviq, and Contrave. The report offers a thorough reports of the competitive landscape of the global diabetes and obesity drugs market and recommends the strategies key players could adopt to remain important in the market. Furthermore, the research report also provides a detailed reports of the research and development activities of these companies, their marketing strategies, and their investment plans for near future in the overall market.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com